Transmission-Blocking Vaccine Against Malaria (1)


A transmission blocking vaccine developed against malaria contains a recombinant virus, which encodes a unique portion of the sexual stage surface antigen of Plasmodium falciparum (referred to as Pfs25), or the Pfs25 protein purified from infected host cells. Mice inoculated with the recombinant virus developed antibodies capable of blocking transmission of the virus. None of the monoclonal antibodies known to block transmission recognize the reduced Pfs25 antigen. This vaccine, which induces high, long-lasting titers at low cost, can be useful for controlling malaria.

Inventors:

David Kaslow (NIAID)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 6,780,417 issued 2004-08-24
US Application No. 08/400,421
PCT Application No. 07/908,765
US Application No. 08/110,457

Licensing Contact:
Benjamin Hurley, Ph.D.
Email: benjamin.hurley@nih.gov
Phone: 240-669-5092

OTT Reference No: E-035-1991-0
Updated: Feb 28, 2011